Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Study tests chronotype’s liver link and finds no significant association

Researchers found no significant association between chronotype and FibroScan-derived liver fat or stiffness in 119 medication-naïve adults with overweight or obesity. The exploratory findings cannot exclude smaller effects, particularly for fibrosis, and require confirmation in larger longitudinal studies.

21 Jul 2026

Study reveals mechanism underlying HBV-induced liver inflammation

Chronic hepatitis B virus (HBV) infection remains a major cause of global liver morbidity, leading to progressive necroinflammation that often culminates in cirrhosis and hepatocellular carcinoma.

17 Jul 2026

Immune pathway may promote the progression of oral precancerous lesions

Researchers at The University of Texas MD Anderson Cancer Center identified an immune pathway that may promote the progression of oral precancerous lesions into head and neck squamous cell carcinoma.

16 Jul 2026

Genome-mining tool reveals new antibiotic hidden in a silent gene cluster

Researchers developed DiscERN, a genome-mining platform that combines four complementary algorithms to identify evolutionarily related biosynthetic gene clusters and prioritize candidates for experimental study. The approach revealed discomycin A, a previously unknown calcium-dependent lipopeptide antibiotic with potent activity against several Gram-positive bacteria.

15 Jul 2026

AI model predicts effective immunotherapy combinations for liver cancer

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular carcinoma (HCC) would most benefit from combination treatment using immunotherapy and a targeted therapy that blocks the growth signals that the tumor depends on.

15 Jul 2026

Integrating gene signatures and multi omics improves liver cancer treatment

Hepatocellular carcinoma (HCC) remains highly fatal due to late diagnosis and scarce early biomarkers.

14 Jul 2026

Study links GLP-1 treatment to fewer alcohol drinking days

Current GLP-1 receptor agonist prescriptions were associated with modestly lower AUDIT-C scores in a large, diverse US cohort. The difference appeared to reflect less frequent drinking rather than fewer drinks per occasion or fewer binge-drinking episodes.

13 Jul 2026

New generation approaches revive BET protein inhibitors in solid tumors

BET proteins, especially BRD4, drive oncogenic transcription in solid tumours. First‑generation inhibitors (JQ1, molibresib, birabresib) showed preclinical promise but failed clinically due to modest efficacy, dose‑limiting thrombocytopenia, and resistance (isoform switching, compensatory PI3K/AKT/WNT signalling).

11 Jul 2026

Microbiome science merges with oncology for better cancer treatments

Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the resident microbiota, to evade immune surveillance and resist conventional therapies.

7 Jul 2026

Case study shows how accurate diagnosis can guide personalized treatment for renal oncocytoma

A new case report was published in Volume 17 of Oncotarget on July 2, 2026, titled "Renal oncocytoma: Α case report and literature review."

6 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Experts reframe steatotic liver disease as a dynamic continuum

The classification of steatotic liver disease (SLD) is undergoing a major conceptual transformation. In a recent article published in eGastroenterology, Dr. Chen, Dr. Horn, and Prof. Tacke from Charité - Universitätsmedizin Berlin argue that metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD) should not be regarded as rigid diagnostic categories, but rather as interconnected and evolving disease trajectories.

30 Jun 2026

Altering gut microbes could improve immunotherapy responses in liver cancer

Immune checkpoint blockade (ICB) has reshaped the treatment landscape for advanced hepatocellular carcinoma (HCC), offering new hope where few options existed.

30 Jun 2026

Obesity drives distinct molecular pathway toward invasive breast cancer

A novel study has found that obesity is associated with a distinct molecular program driving the transition from early-stage, premalignant breast lesions to invasive breast cancer.

30 Jun 2026

FluoGuide announces positive results from Phase 2 oral head and neck cancer trial

FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced positive results from the first part of its ongoing FG001-CT-005 Phase 2 trial evaluating FG001 for surgical guidance in patients with oral head and neck cancer.

30 Jun 2026

Researchers develop new model to study aggressive melanomas

Researchers have created a powerful new cellular model to study rare tumors that are resistant to immunotherapies.

29 Jun 2026

Case report details rare basal cell carcinoma on patient's finger

Basal cell carcinoma is the most prevalent form of skin cancer, typically developing on sun-exposed areas like the face and neck.

26 Jun 2026

New accessible multiplex imaging workflow advances spatial liver research

Spatial biology technologies are reshaping modern biomedical research by enabling the visualization of cellular organization and interactions within intact tissues.

26 Jun 2026

Review outlines key strategies to overcome antibody drug conjugate resistance

The first Antibody-drug conjugate (ADC) was approved overa quarter-century ago, and today more than 20 have reached the clinic.

24 Jun 2026

AI image-based risk scores enable dynamic breast cancer assessment

Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer derived from screening mammograms evolve over time and differ between women who develop cancer and those who do not, opening the door to a new era of dynamic breast cancer risk assessment.

23 Jun 2026